8 Dec 2025
Fine-Tuning Transformers and LLMs for Fake News Detection in Algerian DialectPublisher siteActive, last published 2026
In rheumatoid arthritis research and therapies
Meriem
Sellami
Scholar“Research focused on Rheumatoid Arthritis Research and Therapies and adjacent fields.”
Claim Your Profile9
H-index
227
Citations
Meriem has not officially claimed their profile. If you are Meriem, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
eriem Sellami is a researcher working on Rheumatoid Arthritis Research and Therapies. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Meriem's work has been cited 227 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Rheumatoid Arthritis Research and Therapies×9Spondyloarthritis Studies and Treatments×4Infectious Diseases and Tuberculosis×3Autoimmune and Inflammatory Disorders Research×3Adolescent and Pediatric Healthcare×3
04 · Where I am
Affiliations
Affiliation on published researchUniversity Ferhat Abbas of Setif, AlgeriaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
2 works1 Oct 2023Open access
Tachon's syndrome: Case report and systematic review of the literaturePublisher siteRevista Colombiana de Reumatología (English Edition), Dupuytren's Contracture and Treatments
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Meriem?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you